Skipping randomisation or blinding introduces bias and undermines data credibility. Insist that your CRO follows strict protocols on these fronts to avoid questionable outcomes. Communication gaps also cause trouble. Regular check-ins help catch unexpected problems early, such as adverse reactions during toxicity tests. Immediate discussions allow dose adjustments or protocol tweaks without losing time or money. Data management deserves attention too. Outdated systems without real-time monitoring increase the risk of errors or missed deadlines.
Choose a CRO that uses modern informatics tools for transparent data handling and efficient analysis. You can find options in the UK by exploring preclinical UK CRO providers. Regulatory compliance is another hurdle. CROs unfamiliar with Good Laboratory Practice (GLP) or specific regulatory requirements invite delays during later-stage submissions. Verify your partner’s GLP credentials and experience relevant to your drug’s therapeutic area before signing contracts. Post-study review often gets overlooked but is vital. Initial results don’t tell the whole story; thorough discussions with your CRO can reveal patterns or risks that shape next steps or pivot strategies.
Avoid rushing this phase. Lastly, simple habits make a difference. For example, always double-check that all raw data files match final reports before accepting results. Also, clarify early who owns the data and how documentation will be archived for future audits. Repeatedly confirming these details avoids costly misunderstandings down the line. When selecting a partner, consider their track record on these practical issues and ask about their quality control measures, communication routines, and experience with your type of drug development. The right approach saves resources and keeps your project on track.
